Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

BAY 94-9027 is an extended-half-life, recombinant factor VIII (rFVIII) product conjugated with a 60-kDa branched polyethylene glycol (PEG) molecule indicated for use in previously treated patients (aged ≥ 12 years) with hemophilia A. This randomized, open-label, two-way crossover study compared the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Hematol
Autors principals: Shah, Anita, Solms, Alexander, Wiegmann, Sara, Ahsman, Maurice, Berntorp, Erik, Tiede, Andreas, Iorio, Alfonso, Mancuso, Maria Elisa, Zhivkov, Tihomir, Lissitchkov, Toshko
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700041/
https://ncbi.nlm.nih.gov/pubmed/31236667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03747-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars